Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

biOasis Technologies Ord Shs V.BTI.H

Alternate Symbol(s):  BIOAF

Bioasis Technologies Inc. is a Canada-based biopharmaceutical company focused on research and development of technologies and products intended for the treatment of patients with nervous system, including central nervous system, diseases and disorders. The Company is engaged in the development of its xB 3 platform, which is a peptide-based technology, for the transport of therapeutic agents, in particular biological products, across the blood-brain barrier (BBB). It is focused on both orphan drug indications, including brain cancers, and rare genetic neurodegenerative diseases and neuroinflammatory conditions. The Company is also focused on its Epidermal Growth Factor (EGF) platform for treating rare and orphan neurodegenerative and neuroinflammatory disorders. EGF is a protein that stimulates cell growth and differentiation, notably for myelin producing cells. Its development programs include xB3-001: Brain Metastases, xB3-002: Glioblastoma and xB3-007: Neurodegenerative Disease.


TSXV:BTI.H - Post by User

Post by prophetoffactzon Dec 20, 2022 9:25am
238 Views
Post# 35181777

'Won't find a more full pipeline for a company this size'

'Won't find a more full pipeline for a company this size'Some very rough notes from presentation this morning...

Midatech was hoping for catalysts to do a financing:

Progression free surivivl trial but was delayed by regulators
Q-Sphera deal. couldn't get it over the line. big pharma march to own drummer

Hit:

worst financial market
tourist investors moved on to other sectors.
many biotechs trading below cash

financing extremely difficult.

went with BTI as best option

robust very valuble assets
6 products 6 indications
as platforms brought to proof of concept have a pipeline opportunity

multi-asset news flow

first patient glioblastoma was positive and patient recovering. 
phase II could be enough for other indicatin one patient more to recruit in phase I

merged company won't find a more full pipeline for a company this size.

triial rare and orphan strategy regulators offer shortcuts and exclusivity

five platforms

100,000 X drug in the tumor
in screen of 83 drugs one of most effective. 
DIPG median survival 26 months vs. 10 months. Surprisingly strong result

stat sig in mice
compelling results in human cell lines.



<< Previous
Bullboard Posts
Next >>